🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

149 results for “recombinant” Clear

  1. Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo

    Shanghai University of Traditional Chinese Medicine

    Healthy

    phase 1 small molecule completed

    1 trial

  2. Recombinant NV-A01 adenovirus injection

    The First People's Hospital of Lianyungang

    Advanced Glioblastoma Patients

    phase 1 small molecule active

    1 trial

  3. Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 1 mab completed

    1 trial

  4. Recombinant SARS-CoV-2 Fusion Protein Vaccine

    Livzon Pharmaceutical Group

    COVID19

    phase 1 mab completed

    1 trial

  5. Recombinant adeno-associated virus administration

    Kunming Hope of Health Hospital

    Menkes Syndrome

    phase 1 small molecule terminated

    1 trial

  6. Recombinant erythropoietin stimulating protein

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic Renal Failure

    phase 1 small molecule active

    1 trial

  7. Recombinant human C1 esterase inhibitor

    Takeda

    Hereditary Angioedema (HAE)

    phase 1 small molecule completed

    1 trial

  8. Recombinant human arginase 1 Peg5000

    International Peace Maternity and Child Health Hospital

    Leukemia

    phase 1 small molecule terminated

    1 trial

  9. Recombinant human hyaluronidase PH20 (rHuPH20)

    HALOZYME THERAPEUTICS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  10. Recombinant human thrombopoietin

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Liver Cirrhosis

    phase 1 small molecule active

    1 trial

  11. Recombinant human tissue kallikrein

    DiaMedica Therapeutics

    Stroke

    phase 1 small molecule completed

    1 trial

  12. Recombinant oncolytic herpes simplex virus type Ⅰ (R130)

    Shanghai University of Traditional Chinese Medicine

    Osteosarcoma

    phase 1 small molecule active

    1 trial

  13. Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)

    Takeda

    Von Willebrand Disease

    phase 1 mab completed

    1 trial

  14. Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28

    Jiangsu Province Centers for Disease Control and Prevention

    COVID-19

    phase 1 mab completed

    1 trial

  15. recombinant adenovirus containing the ornithine transcarbamylase gene

    Ultragenyx UK Limited

    Ornithine Transcarbamylase Deficiency Disease

    phase 1 gene therapy terminated

    1 trial

  16. recombinant human thrombopoietin injection

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Liver Disease Chronic

    phase 1 small molecule active

    1 trial

  17. 20 µg recombinant hepatitis B vaccine at months 0, 1, and 6

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatitis B Vaccine

    approved mab active

    3 trials

  18. Abrysvo powder and solvent for solution for injection Respiratory syncytial virus vaccine (bivalent, recombinant)

    Pfizer Australia Pty Ltd

    RSV-infection

    approved small molecule active

    1 trial

  19. Aldurazyme (Recombinant Human Alpha-L-Iduronidase)

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis I

    approved mab completed

    3 trials

  20. Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method

    Takeda

    Hemophilia A

    approved mab completed

    4 trials

  21. Antihemophilic factor, recombinant, manufactured protein-free

    Takeda

    Hemophilia A

    approved small molecule completed

    6 trials

  22. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    approved small molecule active

    1 trial

  23. BIMERVAX LP.8.1 emulsion for injection COVID-19 Vaccine (recombinant, adjuvanted)

    Hipra Human Health S.L.

    COVID-19

    approved small molecule active

    1 trial

  24. BIMERVAX LP.8.1 emulsion for injection COVID-19 Vaccine (recombinant, adjuvanted), Spikevax bivalent Original/Omicron BA.1 25 micrograms/25 micrograms dispersion for injection COVID 19 mRNA Vaccine, Comirnaty 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine, Spikevax 50 micrograms dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine, Comirnaty JN.1 30 micrograms/dose dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine, Nuvaxovid dispersion for injection COVI

    The George Institute

    COVID-19 infection

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources